Incyte Corporation (NASDAQ:INCY) saw its stock surge 7% after the company announced that multiple research presentations, including late-breaking clinical data, have been accepted for the upcoming European Hematology Association (EHA) Annual Congress.
Among the highlights is a highly anticipated oral presentation revealing new findings on INCA033989, a monoclonal antibody targeting mutant calreticulin (mutCALR), in patients with essential thrombocythemia (ET). This investigational therapy is part of Incyte’s broader effort to advance disease-modifying treatments for myeloproliferative neoplasms (MPNs), a class of blood cancers.
The EHA congress, which will be held from June 12 to 15, 2025, in Milan, will serve as a platform for Incyte to showcase progress across its hematology and oncology pipeline. The company also announced it will host an analyst and investor meeting on June 15 to further discuss the new data on mutCALR-targeted therapy.
“We’re excited by the potential of INCA033989 to transform treatment for patients with MPNs like ET,” said Dr. Pablo J. Cagnoni, President and Head of R&D at Incyte. “These data mark a critical step forward in our mission to deliver impactful, disease-altering therapies.”
Beyond INCA033989, Incyte will present updates on several other key investigational treatments. These include INCA035784, a T cell-engaging antibody currently under evaluation, as well as new clinical findings for Ruxolitinib, particularly in the context of myelofibrosis patients with anemia.
Additional poster sessions will highlight Phase 3 data from the Axatilimab program, aimed at chronic graft-versus-host disease, and results from studies involving INCB057643, a BET protein inhibitor for myeloid malignancies.
The market welcomed the announcement, with the stock’s sharp rise reflecting investor confidence in Incyte’s expanding oncology pipeline and the significance of the data set to be unveiled at EHA.